Image Credit: Contract Pharma
Ventus Therapeutics, a leading clinical-level biopharmaceutical company upgrading two phase 2 small-molecule programs for inflammatory, neurological and immunological disorders, has entered a long-term partnership with Genentech. A Genentech is a member of the Roche group that optimises and explores the novel small-molecule candidates for competing the focus-centric evolution in key disease areas with the help of Ventus’s exclusive drug discovery platform ‘RESOLVE®’.
The partnership will bring advancement to the small-molecule medicines and double the potential of Ventus’s resolve platform by integrating into this long-term partnership. This collaboration will pave the way to building innovation in the medication line for better patient outcomes and will gain trust and profit for the partners. The RESOLVE platform is the key performer for future projects and development that will enhance this collaboration.
The ReSOLVE merges the recent advancements in machine learning, structural biology, biophysics, artificial intelligence and protein science to create a dynamic and accurate water chain in protein spectrum. It highlights the hydrocophore® potential to contribute to uplifting optimisation and fuel recognition for novel small-molecule therapeutics at less cost and time than the traditional screening operation.
The PHD, chief scientific officer, Ventus, Michael Crackower said, “The ReSOLVE uniquely presents the shape of water in motion to deeply understand protein structures that alleviates the drug discovery timeline and leverages the patient benefit.” Crackower further added, “Genentech is a global leader in drug discovery known for introducing essential medicines of our time to patients. We’re looking forward to working together to explore more groundbreaking medicines.”
As per the agreement, Ventus will implement ReSOLVE for lead recognition and virtual screening of the novel small molecules in opposition to various targets, and Genentech will organise clinical development, commercialisation and later preclinical development. Moreover, Ventus may accelerate ReSOLVE to contribute to other Genentech-held discovery programs. Ventus will get the upfront payment and will be set eligible for future development, commercial and preclinical milestones crossing around $460 million and a tiered royalty on net sales.
The head of Roche Corporate Business Development, Boris L. Zaitra, said, “Genentech and Roche are consistent in investing in groundbreaking technologies that support us in introducing unique innovative therapies to patients. Partnering with biotech companies like Ventus that bring a spectacular computational idea to the drug exploratory process can create innovative medicines for long-term challenging scenarios.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
